XML 141 R97.htm IDEA: XBRL DOCUMENT v3.22.4
Principal changes in the scope of consolidation in 2022 - Additional Information (Details)
€ / shares in Units, € in Millions, $ in Millions
 8 Months Ended 11 Months Ended 12 Months Ended
Jun. 17, 2022
EUR (€)
May 10, 2022
EUR (€)
€ / shares
shares
May 03, 2022
Mar. 17, 2022
EUR (€)
Oct. 01, 2021
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Feb. 08, 2022
EUR (€)
Feb. 08, 2022
USD ($)
Disclosure of detailed information about business combination [line items]                        
Net cash flow on acquisition [1]               € 992 € 5,594 € 5,336 [2]    
Net sales               42,997 37,761 36,041 [3]    
Exceptional supplementary dividends recognised as distributions to owners of parent [4]               793        
Investments accounted for using the equity method           € 677 € 677 677 250 201 [5]    
Other gains, (losses) and litigation               (370) (5) 136 [3]    
Tax expense (income)               (2,006) (1,558) (1,807) [3]    
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax [6]               134 42 € 0 [2]    
Provision for decommissioning, restoration and rehabilitation costs                        
Disclosure of detailed information about business combination [line items]                        
Other provisions   € 14                    
Regulatory compliance costs                        
Disclosure of detailed information about business combination [line items]                        
Other provisions   € 15                    
Attributable to equity holders of Sanofi                         
Disclosure of detailed information about business combination [line items]                        
Exceptional supplementary dividends recognised as distributions to owners of parent [4]               € 793        
EUROAPI                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in associate (in percent)           30.10%   30.10%        
Ownership interest in subsidiary, minimum holding period   2 years                    
Investments accounted for using the equity method           € 413 413 € 413        
EUROAPI                        
Disclosure of detailed information about business combination [line items]                        
Exceptional supplementary dividend proposed, percentage of share capital       58000000.00%                
Exceptional supplementary dividend, percentage of share capital   58.00% 58.00%                  
Number of shares received (in shares) | shares   1                    
Special Distribution, Number Of Shares Converted | shares   23                    
Special distribution, percentage of share capital distributed   57.88%                    
Net sales                 € 486      
Decrease through loss of control of subsidiary, net assets   € 1,227                    
Decrease through loss of control of subsidiary, intangible assets and goodwill   € 164                    
Weighted average share price (in EUR per share) | € / shares   € 14.58                    
Net foreign exchange loss   € 35                    
Other gains, (losses) and litigation   3                    
Tax expense (income)   111                    
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax   € 101           101        
EUROAPI | Manufacture and supply collaboration agreement                        
Disclosure of detailed information about business combination [line items]                        
Collaboration agreement, period after loss of control         5 years              
Collaboration agreement, annual net sales target         € 300              
Collaboration agreement, commitment amount           € 1,100 1,100 € 1,100        
EUROAPI | EPIC BPIFrance                        
Disclosure of detailed information about business combination [line items]                        
Percentage of voting equity interests divested 12000000.00%     12000000.00%                
Consideration transferred, maximum amount € 150     € 150                
Consideration transferred, valuation period       30 days                
Amunix Pharmaceuticals, Inc                        
Disclosure of detailed information about business combination [line items]                        
Cash transferred                     € 970  
Commitments related to milestone payments, business combinations | $                       $ 225
Contingent consideration recognised as of acquisition date                     156  
Goodwill                     € 609  
Profit (loss) of acquiree since acquisition date             56          
Net cash flow on acquisition             € 852          
[1] (f)    This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note D.2.1.). For 2020, it includes the net cash outflows on the acquisitions of Synthorx and Principia (see Note D.2.2.).
[2] (j)    Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[4] This amount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see note D.1.).
[5] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[6] (h)    For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1).